The future of uveitis treatment

Ophthalmology

Volumn 121, Issue 1, 2014, Pages 365-376

  Lin, Phoebe ^a   Suhler, Eric B ^a,c   Rosenbaum, James T ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DEVERS EYE INSTITUTE   (United States)

^c Portland VA ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; APREMILAST; BELIMUMAB; DEXAMETHASONE; FEZAKINUMAB; FINGOLIMOD; GAMMA INTERFERON; GEVOKIZUMAB; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 23; INTERLEUKIN 6; LYSOPHOSPHATIDIC ACID; OTELIXIZUMAB; RAPAMYCIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 10; RITUXIMAB; SARILUMAB; SECUKINUMAB; SIRUKUMAB; SMALL INTERFERING RNA; SONEPCIZUMAB; SOTRASTAURIN; TABALUMAB; TOCILIZUMAB; TOFACITINIB; UNINDEXED DRUG; USTEKINUMAB;

B LYMPHOCYTE; BIOLOGICAL THERAPY; CELL MIGRATION; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG RESEARCH; DRUG TARGETING; HUMAN; IMMUNE DYSREGULATION; IMMUNOREGULATION; LENS IMPLANT; MAJOR HISTOCOMPATIBILITY COMPLEX; NONVIRAL GENE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUSTAINED DRUG RELEASE; T LYMPHOCYTE ACTIVATION; TARGET CELL; UVEITIS; VIRAL GENE THERAPY;

ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; UVEITIS;

EID: 84891628661     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.08.029     Document Type: Article

References (47)

1. N.R. Benitah, L. Sobrin, and G.N. Papaliodis The use of biologic agents in the treatment of ocular manifestations of Behcet's disease Semin Ophthalmol 26 2011 295 303
2. Y. Qian, and N.R. Acharya Juvenile idiopathic arthritis-associated uveitis Curr Opin Ophthalmol 21 2010 468 472
3. A. Amadi-Obi, C.R. Yu, and X. Liu et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 Nat Med 13 2007 711 718
4. Y. Ke, K. Liu, and G.Q. Huang et al. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis J Immunol 182 2009 3183 3190
5. A.S. Bharadwaj, B. Appukuttan, and P.A. Wilmarth et al. Role of the retinal vascular endothelial cell in ocular disease Prog Retin Eye Res 32 2013 102 180
6. R.W. Read Uveitis: advances in understanding of pathogenesis and treatment Curr Rheumatol Rep 8 2006 260 266
7. M. Mochizuki, S. Sugita, and K. Kamoi Immunological homeostasis of the eye Prog Retin Eye Res 33 2013 10 27
8. A. Gul, I. Tugal-Tutkun, and C.A. Dinarello et al. Interleukin-1beta- regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study Ann Rheum Dis 71 2012 563 566
9. A.D. Dick, I. Tugal-Tutkun, and S. Foster et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials Ophthalmology 120 2013 777 787
10. K. Garber Anti-IL-17 mAbs herald new options in psoriasis Nat Biotechnol 30 2012 475 477
11. B.M. Segal, C.S. Constantinescu, and A. Raychaudhuri et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study Lancet Neurol 7 2008 796 804
12. R. Horai, and R.R. Caspi Cytokines in autoimmune uveitis J Interferon Cytokine Res 31 2011 733 744
13. T. Yoshimura, K.H. Sonoda, and N. Ohguro et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis Rheumatology (Oxford) 48 2009 347 354
14. A. Muselier, P. Bielefeld, and S. Bidot et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis Ocul Immunol Inflamm 19 2011 382 383
15. T. Oshitari, F. Kajita, and A. Tobe et al. Refractory uveitis in patient with Castleman disease successfully treated with tocilizumab Case Rep Ophthalmol Med [serial online] 2012 2012 968180 Available at: http://www.hindawi.com/crim/ ophmed/2012/968180/ Accessed August 17, 2013
16. X. Wu, J.T. Rosenbaum, and G. Adamus et al. Activation of OX40 prolongs and exacerbates autoimmune experimental uveitis Invest Ophthalmol Vis Sci 52 2011 8520 8526
17. G. Adamus, L. Brown, and S. Andrew et al. Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice Invest Ophthalmol Vis Sci 53 2012 406 412
18. G. Adamus, L.J. Karren, J. Mooney, and G.G. Burrows A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis Ophthalmic Res 44 2010 24 33
19. M.A. Zarbin Recombinant T-cell receptor ligands in the treatment of uveitis JAMA Ophthalmol 131 2013 299 400
20. J.F. Huang, R. Yafawi, and M. Zhang et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease [report online] Ophthalmology 119 2012 e43 e50
21. P.H. Schafer, A. Parton, and A.K. Gandhi et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis Br J Pharmacol 159 2010 842 855
22. D.A. Copland, J. Liu, and L.P. Schewitz-Bowers et al. Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier Am J Pathol 180 2012 672 681
23. S. Kurose, E. Ikeda, and M. Tokiwa et al. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats Exp Eye Res 70 2000 7 15
24. N. Jain, and M.T. Bhatti Fingolimod-associated macular edema: incidence, detection, and management Neurology 78 2012 672 680
25. J.H. Stone, P.A. Merkel, and R. Spiera et al. RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis N Engl J Med 363 2010 221 232
26. A. Heiligenhaus, E. Miserocchi, and C. Heinz et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab) Rheumatology (Oxford) 50 2011 1390 1394
27. L. Tian, B. Lei, and J. Shao et al. AAV2-mediated combined subretinal delivery of IFN-alpha and IL-4 reduces the severity of experimental autoimmune uveoretinitis PLoS One [serial online] 7 2012 e37995 Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0037995 Accessed August 17, 2013
28. J.M. Kezic, T.T. Glant, J.T. Rosenbaum, and H.L. Rosenzweig Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis Arthritis Res Ther [serial online] 14 2012 R18 Available at: http://arthritis-research.com/content/14/1/R18 Accessed August 17, 2013
29. J.B. Canavan, B. Afzali, and C. Scotta et al. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy [report online] Blood 119 2012 e57 e66
30. S.R. Thurau, H. Fricke, and C. Burchardi et al. Long-term follow-up of oral tolerance induction with HLA-peptide B27PD in patients with uveitis Ann N Y Acad Sci 1029 2004 408 412
31. T. Liao, Y. Ke, and W.H. Shao et al. Blockade of the interaction of leukotriene b4 with its receptor prevents development of autoimmune uveitis Invest Ophthalmol Vis Sci 47 2006 1543 1549
32. M. Lech, C. Kantner, and O.P. Kulkarni et al. Interleukin-1 receptor-associated kinase-M suppresses systemic lupus erythematosus Ann Rheum Dis 70 2011 2207 2217
33. J.T. Rosenbaum, A. Woods, and J. Kezic et al. Contrasting ocular effects of local versus systemic endotoxin Invest Ophthalmol Vis Sci 52 2011 6472 6477
34. S.M. Bakhtiar, J.G. Leblanc, and E. Salvucci et al. Implications of the human microbiome in inflammatory bowel diseases FEMS Microbiol Lett 342 2013 10 17
35. D.A. Copland, K. Hussain, and S. Baalasubramanian et al. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis Clin Exp Immunol 159 2010 303 314
36. R.W. Read, A.J. Szalai, and S.D. Vogt et al. Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis Exp Eye Res 82 2006 389 394
37. B. Manickam, P. Jha, and N.J. Hepburn et al. Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU) Mol Immunol 48 2010 231 239
38. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Writing Committee, J.H. Kempen, M.M. Altaweel, and J.T. Holbrook et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment trial Ophthalmology 118 2011 1916 1926
39. C. Pavesio, M. Zierhut, and K. Bairi et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis Ophthalmology 117 2010 567 575
40. C. Lowder, R. Belfort Jr., S. Lightman Ozurdex HURON Study Group Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis Arch Ophthalmol 129 2011 545 553
41. S. Eperon, M. Rodriguez-Aller, and K. Balaskas et al. A new drug delivery system inhibits uveitis in an animal model after cataract surgery Int J Pharm 443 2013 254 261
42. B.C. Gilger, D.A. Wilkie, and A.B. Clode et al. Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis Vet Ophthalmol 13 2010 294 300
43. S.R. Chennamaneni, C. Mamalis, and B. Archer et al. Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation J Control Release 167 2013 53 59
44. Y. de Kozak, K. Andrieux, and H. Villarroya et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis Eur J Immunol 34 2004 3702 3712
45. N. Haghjou, M. Soheilian, and M.J. Abdekhodaie Sustained release intraocular drug delivery devices for treatment of uveitis J Ophthalmic Vis Res 6 2011 317 329
46. W.G. Cho, R.J. Albuquerque, and M.E. Kleinman et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth Proc Natl Acad Sci U S A 106 2009 7137 7142
47. E. Touchard, L. Kowalczuk, and C. Bloquel et al. The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins J Gene Med 12 2010 904 919